AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

National Institute of Allergy and Infectious Diseases

 

NIAID to Fund Further Study of Dapivirine Vaginal Ring for HIV Prevention Investment in HOPE Trial Augments Development of Next-Generation Prevention Tools

NIAID image - vaginal ring - ASPIRE study

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today that it would move forward with an open-label extension study of an HIV prevention tool for women: a silicone ring that continuously releases the experimental antiretroviral drug dapivirine in the vagina. The new study builds on…

NIH-Funded Study Finds Critical Population Adheres to PrEP with Coordinated Care

blackmsm

New findings suggest that black men who have sex with men (BMSM) with access to a novel coordinated care program can adhere to pre-exposure prophylaxis (PrEP), a medication regimen that helps prevent HIV infection in uninfected individuals. Researchers reported their results today at a press conference at the Conference on Retroviruses and Opportunistic Infections (CROI)…

Vaginal Ring Provides Partial Protection from HIV in Large Multinational Trial

Woman holding the dapivirine vaginal ring tested in the NIH-funded ASPIRE study.
Credit: International Partnership for Microbicides

NIH-Funded Study Finds Protective Effect Strongest in Women over Age 25 A ring that continuously releases an experimental antiretroviral drug in the vagina safely provided a modest level of protection against HIV infection in women, a large clinical trial in four sub-Saharan African countries has found. The ring reduced the risk of HIV infection by…

The Path to a Cure for Hepatitis C in People with HIV

NIH logo

Hepatitis C can be a chronic condition that leads to liver failure, and treatments often haven’t worked for patients who are also co-infected with HIV. Thanks to research led by the National Institute of Allergy and Infectious Diseases and Gilead Sciences, new therapies are now available that can cure even complicated cases of hepatitis C…

Curing Hard-to-Treat Hepatitis C

hepc_crop

In a new video, NIH researchers and their colleagues from health centers in the District of Columbia discuss efforts to improve treatments for hepatitis C, a potentially life-threatening viral disease that slowly damages the liver. NIH-sponsored clinical studies in the nation’s capital focus on identifying effective, safe, and convenient therapies for hard-to-treat hepatitis C patients,…

BULLETIN: HIV Vaccine Awareness Day 2015

nih logo

May 18, 2015 Vaccination has historically been the best method for protecting against and ultimately defeating mankind’s most devastating infectious diseases. Although the path to developing a safe and effective HIV vaccine has so far been difficult, achieving this goal remains key to realizing a durable end to the global HIV/AIDS pandemic. HIV vaccine development…

HIV Vaccine Awareness Day

Dr. Anthony Fauci

Watch NIAID Director Anthony S. Fauci, M.D., discuss current HIV vaccine research approaches. Developing a safe and sufficiently effective HIV vaccine is essential if we are to achieve a timely and durable end to the global HIV/AIDS pandemic. The path to an HIV vaccine has not been—and will not be—an easy one. In the 27…

NIH Seeks Input on HIV Cure Research Priorities

nih logo

The National Institutes of Health (NIH) is asking the scientific community to weigh in on what should be the highest priority research areas related to understanding HIV persistence and investigating strategies for eradicating or controlling remaining virus despite optimal antiretroviral treatment. Responses will be accepted through March 14 and will help guide the HIV Cure Initiative, a $100 million…